Resmed (RMD) Cost of Revenue (2009 - 2026)

Resmed has reported Cost of Revenue for 18 years, with the latest figure at $540.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 2.87% year-over-year to $540.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 billion (up 2.57% YoY), and the FY2025 full-year result was $2.1 billion, up 3.02% from the prior year.
• Cost of Revenue for Q1 2026 stood at $540.4 million, down from $544.1 million in the prior quarter.
• The five-year high for Cost of Revenue was $550.7 million in Q2 2025, with the low at $362.3 million in Q1 2022.
• Historically, Cost of Revenue has averaged $492.9 million across 5 years, with a median of $507.6 million in 2023.
• Annual changes were most pronounced in 2022 — Cost of Revenue dropped 6.49% — and 2023, when it surged 35.47%.
• Resmed's Cost of Revenue stood at $454.0 million in 2022, then increased by 11.8% to $507.6 million in 2023, then rose by 4.57% to $530.8 million in 2024, then climbed by 2.5% to $544.1 million in 2025, then dropped by 0.67% to $540.4 million in 2026.
• The last three Cost of Revenue figures came in at $540.4 million (Q1 2026), $544.1 million (Q4 2025), and $514.8 million (Q3 2025), per Business Quant data.